Press release

Positive Clinical Trial of GDm-Health™

March 26, 2018

Drayson Health in collaboration with the University of Oxford and Oxford University Hospitals NHS Foundation Trust Announces Positive Clinical Trial Results with GDm-Health™, its Digital Therapeutic Product Powered by Smart Algorithms for the Treatment of Gestational Diabetes

  • Study showed statistically significant improvement in patient satisfaction, adherence to glucose monitoring and a reduction in caesarean sections
  • Trend towards reduction in pre-term births
  • Potential for cost-savings to the NHS through improved patient outcomes
  • One of a number of data-driven health technology applications under development by the company in collaboration with the University of Oxford and Oxford University Hospitals NHS Foundation Trust
  • Study showed statistically significant improvement in patient satisfaction, adherence to glucose monitoring and a reduction in caesarean sections

 [(Median 43, IQR 39-46) in
the GDm-Health group versus (median 44.5, IQR 41-46) in the control group,
(Kruskal-Wallis
2(1)=3.9,
P=.049)]

[mean 3.80 readings per
day, (SD 1.80) in the GDm-Health group and mean 2.63 readings per day, (SD
1.71) in the control group P<.001]

[(27/101,
26.7%) in GDm-Health group versus (47/102, 46.1%) in the control group, P=.005]

[(5/101, 5.0%) in GDm-Health
group versus (13/102, 12.7%; OR 0.36, 95% CI 0.12-1.01) in the control group]

Drayson
Health, in collaboration with the University of Oxford and the Oxford University
Hospitals NHS Foundation Trust, today announces positive results from a study
into the safety and effectiveness of GDm-Health™, a digital therapeutic product
powered by smart algorithms for the treatment of gestational diabetes. The
results were published in

The 203-patient randomised control study
demonstrated equivalent glycaemic control between the GDm-Health group and the
control group (rate of change of blood
glucose (–0.16 mmol/L in the GDm-Health group and –0.14 mmol/L in the control
group per 28 days) and statistically significant improvements in
patient satisfaction with care (P=.049); adherence to blood glucose
monitoring (P<.001) and reduction in caesarean sections (P=.005). There was
also a reduction in pre-term births in the GDm-Health group which did not reach
statistical significance. The difference in mean
health care costs between the GDm-Health group and the control group was –£1044
(95% CI –£2186 to £99), i.e. the GDm-Health group was less expensive, on
average, by more than £1,000, although this did not reach statistical
significance. There
were no adverse events.

Dr Lucy Mackillop, Consultant Obstetric Physician at Oxford University Hospitals NHS Foundation Trust and
Honorary Senior Clinical Lecturer, Nuffield Department of Women’s and Reproductive
Health, University of Oxford; trial leader, lead author of the paper and
clinical lead for the development of GDm-Health said: 
“GDm-Health was developed in partnership
with patients, clinicians and engineers. This trial was conducted in real-world
conditions within the NHS and demonstrates the potential utility of GDm-Health
to improve care and outcomes for women with gestational diabetes and their
babies.”
Lord Drayson, Chairman and CEO of Drayson Health, commented: 
“We are delighted with these clinical trial
results, which underline the GDm-Health product’s safety and efficacy in
improving patient outcomes in gestational diabetes. The progress we are making
in our partnership with Oxford University and Oxford University Hospitals NHS
Foundation Trust to develop
clinically validated software applications powered by artificial intelligence is very encouraging. Our focus now shifts to working
with regulators to make GDm-Health widely available across the UK and
internationally, helping to improve maternal and neo-natal outcomes as
prevalence of diabetes in pregnancy continues to increase.” 

The trial was made possible by funding and
scientific input from the NIHR Oxford Biomedical Research Centre, whose
Technology and Digital Health Theme is led by

“This trial is another example
of how self-management by patients using digital health tools can be secure, gives them greater control of their
condition and reduces the number of times they have to visit clinic. It
improves communication between patient and clinical staff, reduces the amount
of time spent by nurses and midwives on administrative tasks and allows for
accurate auditing of data about care and outcomes.”

Press release

Positive Clinical Trial of GDm-Health™

March 26, 2018

Drayson Health in collaboration with the University of Oxford and Oxford University Hospitals NHS Foundation Trust Announces Positive Clinical Trial Results with GDm-Health™, its Digital Therapeutic Product Powered by Smart Algorithms for the Treatment of Gestational Diabetes

  • Study showed statistically significant improvement in patient satisfaction, adherence to glucose monitoring and a reduction in caesarean sections
  • Trend towards reduction in pre-term births
  • Potential for cost-savings to the NHS through improved patient outcomes
  • One of a number of data-driven health technology applications under development by the company in collaboration with the University of Oxford and Oxford University Hospitals NHS Foundation Trust
  • Study showed statistically significant improvement in patient satisfaction, adherence to glucose monitoring and a reduction in caesarean sections

 [(Median 43, IQR 39-46) in
the GDm-Health group versus (median 44.5, IQR 41-46) in the control group,
(Kruskal-Wallis
2(1)=3.9,
P=.049)]

[mean 3.80 readings per
day, (SD 1.80) in the GDm-Health group and mean 2.63 readings per day, (SD
1.71) in the control group P<.001]

[(27/101,
26.7%) in GDm-Health group versus (47/102, 46.1%) in the control group, P=.005]

[(5/101, 5.0%) in GDm-Health
group versus (13/102, 12.7%; OR 0.36, 95% CI 0.12-1.01) in the control group]

Drayson
Health, in collaboration with the University of Oxford and the Oxford University
Hospitals NHS Foundation Trust, today announces positive results from a study
into the safety and effectiveness of GDm-Health™, a digital therapeutic product
powered by smart algorithms for the treatment of gestational diabetes. The
results were published in

The 203-patient randomised control study
demonstrated equivalent glycaemic control between the GDm-Health group and the
control group (rate of change of blood
glucose (–0.16 mmol/L in the GDm-Health group and –0.14 mmol/L in the control
group per 28 days) and statistically significant improvements in
patient satisfaction with care (P=.049); adherence to blood glucose
monitoring (P<.001) and reduction in caesarean sections (P=.005). There was
also a reduction in pre-term births in the GDm-Health group which did not reach
statistical significance. The difference in mean
health care costs between the GDm-Health group and the control group was –£1044
(95% CI –£2186 to £99), i.e. the GDm-Health group was less expensive, on
average, by more than £1,000, although this did not reach statistical
significance. There
were no adverse events.

Dr Lucy Mackillop, Consultant Obstetric Physician at Oxford University Hospitals NHS Foundation Trust and
Honorary Senior Clinical Lecturer, Nuffield Department of Women’s and Reproductive
Health, University of Oxford; trial leader, lead author of the paper and
clinical lead for the development of GDm-Health said: 
“GDm-Health was developed in partnership
with patients, clinicians and engineers. This trial was conducted in real-world
conditions within the NHS and demonstrates the potential utility of GDm-Health
to improve care and outcomes for women with gestational diabetes and their
babies.”
Lord Drayson, Chairman and CEO of Drayson Health, commented: 
“We are delighted with these clinical trial
results, which underline the GDm-Health product’s safety and efficacy in
improving patient outcomes in gestational diabetes. The progress we are making
in our partnership with Oxford University and Oxford University Hospitals NHS
Foundation Trust to develop
clinically validated software applications powered by artificial intelligence is very encouraging. Our focus now shifts to working
with regulators to make GDm-Health widely available across the UK and
internationally, helping to improve maternal and neo-natal outcomes as
prevalence of diabetes in pregnancy continues to increase.” 

The trial was made possible by funding and
scientific input from the NIHR Oxford Biomedical Research Centre, whose
Technology and Digital Health Theme is led by

“This trial is another example
of how self-management by patients using digital health tools can be secure, gives them greater control of their
condition and reduces the number of times they have to visit clinic. It
improves communication between patient and clinical staff, reduces the amount
of time spent by nurses and midwives on administrative tasks and allows for
accurate auditing of data about care and outcomes.”

Press release

Positive Clinical Trial of GDm-Health™

Positive Clinical Trial of GDm-Health™

March 26, 2018

Drayson Health in collaboration with the University of Oxford and Oxford University Hospitals NHS Foundation Trust Announces Positive Clinical Trial Results with GDm-Health™, its Digital Therapeutic Product Powered by Smart Algorithms for the Treatment of Gestational Diabetes

  • Study showed statistically significant improvement in patient satisfaction, adherence to glucose monitoring and a reduction in caesarean sections
  • Trend towards reduction in pre-term births
  • Potential for cost-savings to the NHS through improved patient outcomes
  • One of a number of data-driven health technology applications under development by the company in collaboration with the University of Oxford and Oxford University Hospitals NHS Foundation Trust
  • Study showed statistically significant improvement in patient satisfaction, adherence to glucose monitoring and a reduction in caesarean sections

 [(Median 43, IQR 39-46) in
the GDm-Health group versus (median 44.5, IQR 41-46) in the control group,
(Kruskal-Wallis
2(1)=3.9,
P=.049)]

[mean 3.80 readings per
day, (SD 1.80) in the GDm-Health group and mean 2.63 readings per day, (SD
1.71) in the control group P<.001]

[(27/101,
26.7%) in GDm-Health group versus (47/102, 46.1%) in the control group, P=.005]

[(5/101, 5.0%) in GDm-Health
group versus (13/102, 12.7%; OR 0.36, 95% CI 0.12-1.01) in the control group]

Drayson
Health, in collaboration with the University of Oxford and the Oxford University
Hospitals NHS Foundation Trust, today announces positive results from a study
into the safety and effectiveness of GDm-Health™, a digital therapeutic product
powered by smart algorithms for the treatment of gestational diabetes. The
results were published in

The 203-patient randomised control study
demonstrated equivalent glycaemic control between the GDm-Health group and the
control group (rate of change of blood
glucose (–0.16 mmol/L in the GDm-Health group and –0.14 mmol/L in the control
group per 28 days) and statistically significant improvements in
patient satisfaction with care (P=.049); adherence to blood glucose
monitoring (P<.001) and reduction in caesarean sections (P=.005). There was
also a reduction in pre-term births in the GDm-Health group which did not reach
statistical significance. The difference in mean
health care costs between the GDm-Health group and the control group was –£1044
(95% CI –£2186 to £99), i.e. the GDm-Health group was less expensive, on
average, by more than £1,000, although this did not reach statistical
significance. There
were no adverse events.

Dr Lucy Mackillop, Consultant Obstetric Physician at Oxford University Hospitals NHS Foundation Trust and
Honorary Senior Clinical Lecturer, Nuffield Department of Women’s and Reproductive
Health, University of Oxford; trial leader, lead author of the paper and
clinical lead for the development of GDm-Health said: 
“GDm-Health was developed in partnership
with patients, clinicians and engineers. This trial was conducted in real-world
conditions within the NHS and demonstrates the potential utility of GDm-Health
to improve care and outcomes for women with gestational diabetes and their
babies.”
Lord Drayson, Chairman and CEO of Drayson Health, commented: 
“We are delighted with these clinical trial
results, which underline the GDm-Health product’s safety and efficacy in
improving patient outcomes in gestational diabetes. The progress we are making
in our partnership with Oxford University and Oxford University Hospitals NHS
Foundation Trust to develop
clinically validated software applications powered by artificial intelligence is very encouraging. Our focus now shifts to working
with regulators to make GDm-Health widely available across the UK and
internationally, helping to improve maternal and neo-natal outcomes as
prevalence of diabetes in pregnancy continues to increase.” 

The trial was made possible by funding and
scientific input from the NIHR Oxford Biomedical Research Centre, whose
Technology and Digital Health Theme is led by

“This trial is another example
of how self-management by patients using digital health tools can be secure, gives them greater control of their
condition and reduces the number of times they have to visit clinic. It
improves communication between patient and clinical staff, reduces the amount
of time spent by nurses and midwives on administrative tasks and allows for
accurate auditing of data about care and outcomes.”

Press release

Positive Clinical Trial of GDm-Health™

Positive Clinical Trial of GDm-Health™

Drayson Health in collaboration with the University of Oxford and Oxford University Hospitals NHS Foundation Trust Announces Positive Clinical Trial Results with GDm-Health™, its Digital Therapeutic Product Powered by Smart Algorithms for the Treatment of Gestational Diabetes

  • Study showed statistically significant improvement in patient satisfaction, adherence to glucose monitoring and a reduction in caesarean sections
  • Trend towards reduction in pre-term births
  • Potential for cost-savings to the NHS through improved patient outcomes
  • One of a number of data-driven health technology applications under development by the company in collaboration with the University of Oxford and Oxford University Hospitals NHS Foundation Trust
  • Study showed statistically significant improvement in patient satisfaction, adherence to glucose monitoring and a reduction in caesarean sections

 [(Median 43, IQR 39-46) in
the GDm-Health group versus (median 44.5, IQR 41-46) in the control group,
(Kruskal-Wallis
2(1)=3.9,
P=.049)]

[mean 3.80 readings per
day, (SD 1.80) in the GDm-Health group and mean 2.63 readings per day, (SD
1.71) in the control group P<.001]

[(27/101,
26.7%) in GDm-Health group versus (47/102, 46.1%) in the control group, P=.005]

[(5/101, 5.0%) in GDm-Health
group versus (13/102, 12.7%; OR 0.36, 95% CI 0.12-1.01) in the control group]

Drayson
Health, in collaboration with the University of Oxford and the Oxford University
Hospitals NHS Foundation Trust, today announces positive results from a study
into the safety and effectiveness of GDm-Health™, a digital therapeutic product
powered by smart algorithms for the treatment of gestational diabetes. The
results were published in

The 203-patient randomised control study
demonstrated equivalent glycaemic control between the GDm-Health group and the
control group (rate of change of blood
glucose (–0.16 mmol/L in the GDm-Health group and –0.14 mmol/L in the control
group per 28 days) and statistically significant improvements in
patient satisfaction with care (P=.049); adherence to blood glucose
monitoring (P<.001) and reduction in caesarean sections (P=.005). There was
also a reduction in pre-term births in the GDm-Health group which did not reach
statistical significance. The difference in mean
health care costs between the GDm-Health group and the control group was –£1044
(95% CI –£2186 to £99), i.e. the GDm-Health group was less expensive, on
average, by more than £1,000, although this did not reach statistical
significance. There
were no adverse events.

Dr Lucy Mackillop, Consultant Obstetric Physician at Oxford University Hospitals NHS Foundation Trust and
Honorary Senior Clinical Lecturer, Nuffield Department of Women’s and Reproductive
Health, University of Oxford; trial leader, lead author of the paper and
clinical lead for the development of GDm-Health said: 
“GDm-Health was developed in partnership
with patients, clinicians and engineers. This trial was conducted in real-world
conditions within the NHS and demonstrates the potential utility of GDm-Health
to improve care and outcomes for women with gestational diabetes and their
babies.”
Lord Drayson, Chairman and CEO of Drayson Health, commented: 
“We are delighted with these clinical trial
results, which underline the GDm-Health product’s safety and efficacy in
improving patient outcomes in gestational diabetes. The progress we are making
in our partnership with Oxford University and Oxford University Hospitals NHS
Foundation Trust to develop
clinically validated software applications powered by artificial intelligence is very encouraging. Our focus now shifts to working
with regulators to make GDm-Health widely available across the UK and
internationally, helping to improve maternal and neo-natal outcomes as
prevalence of diabetes in pregnancy continues to increase.” 

The trial was made possible by funding and
scientific input from the NIHR Oxford Biomedical Research Centre, whose
Technology and Digital Health Theme is led by

“This trial is another example
of how self-management by patients using digital health tools can be secure, gives them greater control of their
condition and reduces the number of times they have to visit clinic. It
improves communication between patient and clinical staff, reduces the amount
of time spent by nurses and midwives on administrative tasks and allows for
accurate auditing of data about care and outcomes.”

Arrange to meet us
Press release

Positive Clinical Trial of GDm-Health™

March 26, 2018

Drayson Health in collaboration with the University of Oxford and Oxford University Hospitals NHS Foundation Trust Announces Positive Clinical Trial Results with GDm-Health™, its Digital Therapeutic Product Powered by Smart Algorithms for the Treatment of Gestational Diabetes

  • Study showed statistically significant improvement in patient satisfaction, adherence to glucose monitoring and a reduction in caesarean sections
  • Trend towards reduction in pre-term births
  • Potential for cost-savings to the NHS through improved patient outcomes
  • One of a number of data-driven health technology applications under development by the company in collaboration with the University of Oxford and Oxford University Hospitals NHS Foundation Trust
  • Study showed statistically significant improvement in patient satisfaction, adherence to glucose monitoring and a reduction in caesarean sections

 [(Median 43, IQR 39-46) in
the GDm-Health group versus (median 44.5, IQR 41-46) in the control group,
(Kruskal-Wallis
2(1)=3.9,
P=.049)]

[mean 3.80 readings per
day, (SD 1.80) in the GDm-Health group and mean 2.63 readings per day, (SD
1.71) in the control group P<.001]

[(27/101,
26.7%) in GDm-Health group versus (47/102, 46.1%) in the control group, P=.005]

[(5/101, 5.0%) in GDm-Health
group versus (13/102, 12.7%; OR 0.36, 95% CI 0.12-1.01) in the control group]

Drayson
Health, in collaboration with the University of Oxford and the Oxford University
Hospitals NHS Foundation Trust, today announces positive results from a study
into the safety and effectiveness of GDm-Health™, a digital therapeutic product
powered by smart algorithms for the treatment of gestational diabetes. The
results were published in

The 203-patient randomised control study
demonstrated equivalent glycaemic control between the GDm-Health group and the
control group (rate of change of blood
glucose (–0.16 mmol/L in the GDm-Health group and –0.14 mmol/L in the control
group per 28 days) and statistically significant improvements in
patient satisfaction with care (P=.049); adherence to blood glucose
monitoring (P<.001) and reduction in caesarean sections (P=.005). There was
also a reduction in pre-term births in the GDm-Health group which did not reach
statistical significance. The difference in mean
health care costs between the GDm-Health group and the control group was –£1044
(95% CI –£2186 to £99), i.e. the GDm-Health group was less expensive, on
average, by more than £1,000, although this did not reach statistical
significance. There
were no adverse events.

Dr Lucy Mackillop, Consultant Obstetric Physician at Oxford University Hospitals NHS Foundation Trust and
Honorary Senior Clinical Lecturer, Nuffield Department of Women’s and Reproductive
Health, University of Oxford; trial leader, lead author of the paper and
clinical lead for the development of GDm-Health said: 
“GDm-Health was developed in partnership
with patients, clinicians and engineers. This trial was conducted in real-world
conditions within the NHS and demonstrates the potential utility of GDm-Health
to improve care and outcomes for women with gestational diabetes and their
babies.”
Lord Drayson, Chairman and CEO of Drayson Health, commented: 
“We are delighted with these clinical trial
results, which underline the GDm-Health product’s safety and efficacy in
improving patient outcomes in gestational diabetes. The progress we are making
in our partnership with Oxford University and Oxford University Hospitals NHS
Foundation Trust to develop
clinically validated software applications powered by artificial intelligence is very encouraging. Our focus now shifts to working
with regulators to make GDm-Health widely available across the UK and
internationally, helping to improve maternal and neo-natal outcomes as
prevalence of diabetes in pregnancy continues to increase.” 

The trial was made possible by funding and
scientific input from the NIHR Oxford Biomedical Research Centre, whose
Technology and Digital Health Theme is led by

“This trial is another example
of how self-management by patients using digital health tools can be secure, gives them greater control of their
condition and reduces the number of times they have to visit clinic. It
improves communication between patient and clinical staff, reduces the amount
of time spent by nurses and midwives on administrative tasks and allows for
accurate auditing of data about care and outcomes.”